Vimarsana
Biggest News Aggregation in the World

Hans Thomas News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hans Thomas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hans Thomas Today - Breaking & Trending Today

10X Capital Venture Acquisition Corp. III Announces Expected Change in Management - Vimarsana News

10X Capital Venture Acquisition Corp. III Announces Expected Change in Management

NEW YORK, NY , Jan. 08, 2024 -- 10X Capital Venture Acquisition Corp. III , a publicly traded special purpose acquisition company, announced today that, subject to approval by the board of...

Billionaire Superyacht Showdown: Who's Who In St. Barths For New Years 2024 - Vimarsana News

Billionaire Superyacht Showdown: Who's Who In St. Barths For New Years 2024

The festive season started early with the wealthiest men in the world and their celebrity friends anchored outside of Gustavia and neighboring St. Maarten and Antigua.

Source: forbes.com
10X Capital Venture Acquisition Corp. II and African Agriculture, Inc. Announce Closing of Business Combination - Vimarsana News

10X Capital Venture Acquisition Corp. II and African Agriculture, Inc. Announce Closing of Business Combination

Poised to Capture a Meaningful Share of the $21 Billion Global Alfalfa Market Trading Expected to Commence on Nasdaq Global Market December 7, 2023 under Ticker “AAGR” Announces Name Change to African Agriculture NEW YORK, NY, Dec. 06, 2023 (GLOBE NEWSWIRE) -- 10X Capital Venture Acquisition Corp. II (“10X II”) (NASDAQ:VCXA), a publicly traded special purpose acquisition company, announced today that it has completed its previously announced merger with African Agriculture, Inc., a global food s

Source: yahoo.com
Correction: Addimmune, a Clinical Stage HIV-Focused Gene Therapy Company, to go Public Through Business Combination With 10X Capital Venture Acquisition Corp. III - Vimarsana News

Correction: Addimmune, a Clinical Stage HIV-Focused Gene Therapy Company, to go Public Through Business Combination With 10X Capital Venture Acquisition Corp. III

Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells that harden those cells against HIV infection and depletion, thus allowing those cells...

Correction: Addimmune, a Clinical Stage HIV-Focused Gene - Vimarsana News

Correction: Addimmune, a Clinical Stage HIV-Focused Gene

Addimmune’s investigational cell therapy, AGT103-T, makes gene modifications to the patients’ immune cells (T cells) that harden those cells against HIV...